source
- Sleuth predicts surge in Western licensing of Chinese radioligand therapies by 2027Sleuth, a biopharma intelligence platform, says that while Chinese radiopharmaceutical assets have seen few licensing deals so far, the market is set to change. The firm notes that China now runs…
- Novo outlines $23 billion 2035 revenue target, but investors react with a 7% share dropNovo’s chief executive used the recent Capital Markets Day to lay out a long‑term growth plan that targets $23 billion in annual sales by 2035. The strategy emphasizes expanding beyond its flagship…